Published • loading... • Updated
Proteotype Unveils Alchemi®, the Data and Orchestration Platform Behind Enlighten®
The platform is backed by about $499,000 to standardize lab data and support secure deployment across distributed laboratories.
- Yesterday, Torres Vedras, Portugal-based Proteotype Diagnostics unveiled Alchemi, a proprietary data and clinical workflow platform designed for Enlighten, the company's investigational blood-based multi-cancer test.
- The 15-month development programme begins September 1, 2026, supported by approximately €499,000 from the European Innovation Council's Pre-Accelerator funding initiative.
- Alchemi connects laboratory measurements and multi-country clinical data through secure digital infrastructure, supporting interoperability standards including HL7 FHIR and SNOMED to simplify local care pathways.
- CEO Wesley Sukdao said Alchemi provides the software infrastructure required to turn laboratory measurements into reliable results, while Chief Scientific Officer Emma Yates emphasized managing complexity while keeping Enlighten scalable.
- Development will be led from Proteotype's Torres Vedras site, where the company is recruiting full-time roles in software engineering, data engineering, and cybersecurity.
Insights by Ground AI
24 Articles
24 Articles
Proteotype Unveils Alchemi®, the Data and Orchestration Platform Behind Enlighten®
With approximately €499,000 from the EIC Pre-Accelerator, Alchemi® is being developed to connect laboratory measurements, multi-country clinical data and healthcare workflows, supporting secure, interoperable deployment across distributed laboratories.
·Pennsylvania, United States
Read Full Article
Coverage Details
Total News Sources24
Leaning Left1Leaning Right2Center18Last UpdatedBias Distribution86% Center
Bias Distribution
- 86% of the sources are Center
86% Center
C 86%
Factuality
To view factuality data please Upgrade to Premium
